RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE.

This page is a neutral bibliography for qualified researchers. It does not provide medical advice, dosing information, treatment recommendations, reconstitution instructions, administration protocols, or suggestions for human or veterinary use.

The publications below concern materials and protocols selected by independent investigators. None evaluates an Amino Fusion Labs product. Inclusion does not establish product identity, purity, quality, safety, effectiveness, FDA approval, or suitability for any use.

REGULATORY AND COMPLIANCE SOURCES

U.S. Food and Drug Administration. “Gram Peptides” warning letter (March 31, 2026). Addresses products promoted as research-only while website content indicates intended human use.

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026

U.S. Food and Drug Administration. “Royal Peptides LLC” warning letter (August 24, 2026).

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026

U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.”

https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

U.S. Food and Drug Administration. “Using Fat-Dissolving Injections That Are Not FDA Approved Can Be Harmful.”

https://www.fda.gov/drugs/buying-using-medicine-safely/using-fat-dissolving-injections-are-not-fda-approved-can-be-harmful

U.S. Federal Trade Commission. “Health Products Compliance Guidance.”

https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance

SELECTED INDEPENDENT SCIENTIFIC LITERATURE

Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine, 2023. PubMed PMID: 37366315.

https://pubmed.ncbi.nlm.nih.gov/37366315/

Rosenstock J, et al. “Retatrutide … in people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.” The Lancet, 2023. PubMed PMID: 37385280.

https://pubmed.ncbi.nlm.nih.gov/37385280/

Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022. PubMed PMID: 37385275.

https://pubmed.ncbi.nlm.nih.gov/37385275/

Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” International Journal of Molecular Sciences, 2018. PubMed PMID: 29986520.

https://pubmed.ncbi.nlm.nih.gov/29986520/

Human clinical publications listed here evaluated independently manufactured investigational or approved drug products under specific protocols. They do not support administration of any Amino Fusion Labs product.